- Trial phase
- Phase 1
- Time to market
- Unknown, LX9851 is in Phase 1; if successful, approval would likely be 5-7+ years away, though as a partnered program with Novo Nordisk the timeline is at Novo Nordisk's discretion.
- Why 5/10
- LX9851's next hard catalyst is Phase 1 trial completion expected in Q1 2027 (~4-7 months away). This is a partnered early-stage program, not Lexicon's lead asset, the company's primary near-term value drivers are ZYNQUISTA NDA resubmission (Q4 2026) and SONATA-HCM Phase 3 topline (Q1 2027). LX9851 is a meaningful pipeline asset but not a make-or-break binary for LXRX.
LX9851 is a partnered early-stage asset, the stock will primarily trade on Lexicon's nearer-term catalysts (ZYNQUISTA NDA resubmission in Q4 2026 and SONATA-HCM Phase 3 topline in Q1 2027). The next LX9851-specific catalyst is Phase 1 completion expected Q1 2027, which could trigger additional milestone payments from Novo Nordisk. Monitor for any Phase 1 data disclosures or further milestone achievements.
Price Chart
Executive Summary
LX9851 is a first-in-class oral non-incretin obesity drug candidate discovered by Lexicon Pharmaceuticals (LXRX) and being developed by Novo Nordisk (NVO) under a licensing partnership. Novo Nordisk initiated a Phase 1 trial in March 2026, triggering a $10M milestone payment to Lexicon, and a third $10M milestone was earned in August 2026. Lexicon is eligible for up to $1 billion in total milestones plus tiered royalties. The Phase 1 trial (96 subjects with overweight/obesity) is expected to complete in Q1 2027. While the Novo Nordisk partnership provides validation and non-dilutive funding, LX9851 is an early-stage partnered asset and not Lexicon's primary near-term value driver, that role belongs to ZYNQUISTA (NDA resubmission Q4 2026) and SONATA-HCM (Phase 3 topline Q1 2027).
How It Works
LX9851 is a first-in-class, oral (pill-based) non-incretin drug candidate for obesity. Unlike popular GLP-1 drugs (like Ozempic/Wegovy) that mimic a natural hormone to suppress appetite and slow digestion, LX9851 works through a different biological pathway. Preclinical studies suggest it may enhance weight loss when combined with GLP-1 drugs like semaglutide, potentially offering a new oral treatment option for obesity and related metabolic disorders.
Trial Status
Phase 1 trial initiated by Novo Nordisk in March 2026, evaluating safety, tolerability, and pharmacokinetics in 96 individuals with overweight or obesity. Completion expected Q1 2027. A key Phase 1 development milestone was achieved in August 2026, triggering a third $10M milestone payment to Lexicon.
The Two-Sided Case
Upcoming Catalysts
- Phase 1 trial completion expected Q1 2027
- Potential additional milestone payments from Novo Nordisk upon achieving further development milestones
- Any Phase 1 data disclosures or presentations at medical conferences
Source Filing
The SecBot filing or press-release report that triggered this drug report:
LEXICON PHARMACEUTICALS, INC. 8-K LXRX ·Originating report